AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

SCNI · NASDAQ · Biotechnology

Scinai Immunotherapeutics (ADR) (SCNI)

Runs an Israeli CDMO alongside antibody programs for inflammation and immunology.

$2.04

Pre-market−0.31 (−13.19%)

At close$2.35(−4.47%)

Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

129 ADS as of Aug 25, 2026 · holders as of their latest filing

The share count has not been confirmed by a second filing; stakes use it as it stands.

Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.

Top shareholders13F · 13D/G · Form 4

Holder	Stake	Shares	Evidence
Uri Ben-Or¹Insiderdirector	—	—	Form 4filed Mar 18, 2026 ↗
Mark Germain¹Insiderdirector	—	—	Form 4filed Jun 18, 2026 ↗
Jay GreenInsiderdirector	0.00%	0	Form 4filed Mar 18, 2026 ↗
LCK JNK 1 LLCStrategic	—9.50% of class, as filed	—	13Gfiled Mar 4, 2025 ↗
Yael MargolinInsiderdirector	0.00%	0	Form 4filed Mar 18, 2026 ↗
Elad Mark¹Insiderofficer: Chief Operating Officer	—	—	Form 4filed Mar 26, 2026 ↗
Samuel J. MoedInsiderdirector	0.00%	0	Form 4filed Mar 18, 2026 ↗
Adi RavivInsiderdirector	0.00%	0	Form 4filed Mar 18, 2026 ↗
Amir Reichman¹Insiderdirector, officer: Chief Executive Officer	—	—	Form 4filed Jun 18, 2026 ↗
Stone Daniel E.Insider	—9.90% of class, as filed	—	13Gfiled Jul 1, 2026 ↗
YA II PN, Ltd.Strategic	—9.90% of class, as filed	—	13Gfiled Mar 26, 2025 ↗

This position is filed in underlying shares, not receipts; the ratio is unknown, so no percentage.

13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F

No 13F holders on record.

Ownership statements13D/G · 5% or more, as filed

Holder	% of class	Form	Filed
Stone Daniel E.	9.90%	13G	Jul 1, 2026 ↗
YA II PN, Ltd.	9.90%	13G	Mar 26, 2025 ↗
LCK JNK 1 LLC	9.50%	13G	Mar 4, 2025 ↗

Scinai Immunotherapeutics (ADR) (SCNI)

Breakdown13F · 13D/G · Form 4

Top shareholders13F · 13D/G · Form 4

Institutions13F

Ownership statements13D/G · 5% or more, as filed

Insider tradesForm 4

Latest trades

CongressHouse and Senate disclosures